乳癌用ER標的薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

• 英文タイトル：Global ER Targeted Drugs for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024

• レポートコード：B-GIR08C2121
• 出版社/出版日：GlobalInfoResearch / 2019年8月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、135ページ
• 納品方法：Eメール
• 産業分類：Pharma & Healthcare

• 販売価格（消費税別）

Single User	￥501,120 (USD3,480)	▷ お問い合わせ
Corporate User	￥1,002,240 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

本調査レポートは、乳癌用ER標的薬の世界市場について調べ、まとめました。種類別セグメントは、タモキシフェン、トレミフェン、フルベストラント等、用途別セグメントは、病院、診療所、その他等に区分しました。乳癌用ER標的薬の世界市場概観、企業動向、企業別乳癌用ER標的薬シェア、市場規模推移、市場規模予測（2019年-2024年）、主要地域分析（北米、ヨーロッパ、アジア等）、主要国分析（日本、中国、アメリカ等）データなどの情報が含まれています。
・乳癌用ER標的薬の市場概観
・乳癌用ER標的薬の企業概要（事業概要、製品種類、販売量、価格、売上、市場シェア等）
・乳癌用ER標的薬の企業別販売動向、市場シェア、市場集中度、競争動向
・乳癌用ER標的薬の世界市場規模
・乳癌用ER標的薬の北米市場分析（アメリカ、カナダ、メキシコ等）
・乳癌用ER標的薬のアメリカ市場規模推移
・乳癌用ER標的薬のカナダ市場規模推移
・乳癌用ER標的薬のメキシコ市場規模推移
・乳癌用ER標的薬のヨーロッパ市場分析（ドイツ、イギリス、ロシア、フランス、イタリア等）
・乳癌用ER標的薬のドイツ市場規模推移
・乳癌用ER標的薬のイギリス市場規模推移
・乳癌用ER標的薬のロシア市場規模推移
・乳癌用ER標的薬のアジア太平洋市場分析（日本、中国、韓国、インド、東南アジア等）
・乳癌用ER標的薬の日本市場規模推移
・乳癌用ER標的薬の中国市場規模推移
・乳癌用ER標的薬の韓国市場規模推移
・乳癌用ER標的薬のインド市場規模推移
・乳癌用ER標的薬の東南アジア市場規模推移
・乳癌用ER標的薬の南米市場分析（ブラジル、アルゼンチン等）
・乳癌用ER標的薬の中東・アフリカ市場分析（サウジアラビア、UAE、南アフリカ等）
・乳癌用ER標的薬の種類別分析/販売量、売上、市場シェア（タモキシフェン、トレミフェン、フルベストラント）
・乳癌用ER標的薬の用途別分析/市場規模（病院、診療所、その他）
・乳癌用ER標的薬の市場予測2019年-2024年（地域別予測、種類別予測、用途別予測）
・乳癌用ER標的薬の販売チャネル・代理店・貿易業者・ディーラー分析

Scope of the Report:
The global ER Targeted Drugs for Breast Cancer market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of ER Targeted Drugs for Breast Cancer.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the ER Targeted Drugs for Breast Cancer market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the ER Targeted Drugs for Breast Cancer market by product type and applications/end industries.

Market Segment by Companies, this report covers
AstraZeneca
Sanofi
Pfizer
Mylan
Wockhardt
Cipla
Actiza Pharmaceutical
Teva
Shanghai Forward Technology
Bayer
Liaoning Kangtai Pharmaceutical
Fu ‘an Pharmaceutical Group
Yangtze River Pharmaceutical Group
Amneal Pharms
Novartis
Intas Pharmaceuticals
Chemo
Accure Labs
Natco
Orion Corporation
Kyowa Hakko Kirin

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Tamoxifen
Toremifene
Fulvestrant

Market Segment by Applications, can be divided into
Hospital
Clinic
Drug Center
Other

レポート目次

Table of Contents

1 ER Targeted Drugs for Breast Cancer Market Overview
1.1 Product Overview and Scope of ER Targeted Drugs for Breast Cancer
1.2 Classification of ER Targeted Drugs for Breast Cancer by Types
1.2.1 Global ER Targeted Drugs for Breast Cancer Revenue Comparison by Types (2019-2024)
1.2.2 Global ER Targeted Drugs for Breast Cancer Revenue Market Share by Types in 2018
1.2.3 Tamoxifen
1.2.4 Toremifene
1.2.5 Fulvestrant
1.3 Global ER Targeted Drugs for Breast Cancer Market by Application
1.3.1 Global ER Targeted Drugs for Breast Cancer Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Global ER Targeted Drugs for Breast Cancer Market by Regions
1.4.1 Global ER Targeted Drugs for Breast Cancer Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) ER Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) ER Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) ER Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) ER Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) ER Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
1.5 Global Market Size of ER Targeted Drugs for Breast Cancer (2014-2024)
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 Business Overview
2.1.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 AstraZeneca ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.2 Sanofi
2.2.1 Business Overview
2.2.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Sanofi ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.3 Pfizer
2.3.1 Business Overview
2.3.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Pfizer ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.4 Mylan
2.4.1 Business Overview
2.4.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Mylan ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.5 Wockhardt
2.5.1 Business Overview
2.5.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Wockhardt ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.6 Cipla
2.6.1 Business Overview
2.6.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Cipla ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.7 Actiza Pharmaceutical
2.7.1 Business Overview
2.7.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Actiza Pharmaceutical ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.8 Teva
2.8.1 Business Overview
2.8.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Teva ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.9 Shanghai Forward Technology
2.9.1 Business Overview
2.9.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Shanghai Forward Technology ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.10 Bayer
2.10.1 Business Overview
2.10.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Bayer ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.11 Liaoning Kangtai Pharmaceutical
2.11.1 Business Overview
2.11.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Liaoning Kangtai Pharmaceutical ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.12 Fu ‘an Pharmaceutical Group
2.12.1 Business Overview
2.12.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Fu ‘an Pharmaceutical Group ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.13 Yangtze River Pharmaceutical Group
2.13.1 Business Overview
2.13.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Yangtze River Pharmaceutical Group ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.14 Amneal Pharms
2.14.1 Business Overview
2.14.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Amneal Pharms ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.15 Novartis
2.15.1 Business Overview
2.15.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Novartis ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.16 Intas Pharmaceuticals
2.16.1 Business Overview
2.16.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Intas Pharmaceuticals ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.17 Chemo
2.17.1 Business Overview
2.17.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Chemo ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.18 Accure Labs
2.18.1 Business Overview
2.18.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Accure Labs ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.19 Natco
2.19.1 Business Overview
2.19.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Natco ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.20 Orion Corporation
2.20.1 Business Overview
2.20.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 Orion Corporation ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.21 Kyowa Hakko Kirin
2.21.1 Business Overview
2.2.2 ER Targeted Drugs for Breast Cancer Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 Kyowa Hakko Kirin ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
3 Global ER Targeted Drugs for Breast Cancer Market Competition, by Players
3.1 Global ER Targeted Drugs for Breast Cancer Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 ER Targeted Drugs for Breast Cancer Players Market Share
3.2.2 Top 10 ER Targeted Drugs for Breast Cancer Players Market Share
3.3 Market Competition Trend
4 Global ER Targeted Drugs for Breast Cancer Market Size by Regions
4.1 Global ER Targeted Drugs for Breast Cancer Revenue and Market Share by Regions
4.2 North America ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
4.3 Europe ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
4.5 South America ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
5 North America ER Targeted Drugs for Breast Cancer Revenue by Countries
5.1 North America ER Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
5.2 USA ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
5.3 Canada ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
5.4 Mexico ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
6 Europe ER Targeted Drugs for Breast Cancer Revenue by Countries
6.1 Europe ER Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
6.2 Germany ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
6.3 UK ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
6.4 France ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
6.5 Russia ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
6.6 Italy ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
7 Asia-Pacific ER Targeted Drugs for Breast Cancer Revenue by Countries
7.1 Asia-Pacific ER Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
7.2 China ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
7.3 Japan ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
7.4 Korea ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
7.5 India ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
8 South America ER Targeted Drugs for Breast Cancer Revenue by Countries
8.1 South America ER Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
8.2 Brazil ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
8.3 Argentina ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
8.4 Colombia ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue ER Targeted Drugs for Breast Cancer by Countries
9.1 Middle East and Africa ER Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
9.2 Saudi Arabia ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
9.3 UAE ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
9.4 Egypt ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
9.5 Nigeria ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
9.6 South Africa ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
10 Global ER Targeted Drugs for Breast Cancer Market Segment by Type
10.1 Global ER Targeted Drugs for Breast Cancer Revenue and Market Share by Type (2014-2019)
10.2 Global ER Targeted Drugs for Breast Cancer Market Forecast by Type (2019-2024)
10.3 Tamoxifen Revenue Growth Rate (2014-2024)
10.4 Toremifene Revenue Growth Rate (2014-2024)
10.5 Fulvestrant Revenue Growth Rate (2014-2024)
11 Global ER Targeted Drugs for Breast Cancer Market Segment by Application
11.1 Global ER Targeted Drugs for Breast Cancer Revenue Market Share by Application (2014-2019)
11.2 ER Targeted Drugs for Breast Cancer Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2014-2019)
11.4 Clinic Revenue Growth (2014-2019)
11.5 Drug Center Revenue Growth (2014-2019)
11.6 Other Revenue Growth (2014-2019)
12 Global ER Targeted Drugs for Breast Cancer Market Size Forecast (2019-2024)
12.1 Global ER Targeted Drugs for Breast Cancer Market Size Forecast (2019-2024)
12.2 Global ER Targeted Drugs for Breast Cancer Market Forecast by Regions (2019-2024)
12.3 North America ER Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
12.4 Europe ER Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific ER Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
12.6 South America ER Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa ER Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source

List of Tables and Figures

Figure ER Targeted Drugs for Breast Cancer Picture
Table Product Specifications of ER Targeted Drugs for Breast Cancer
Table Global ER Targeted Drugs for Breast Cancer and Revenue (Million USD) Market Split by Product Type
Figure Global ER Targeted Drugs for Breast Cancer Revenue Market Share by Types in 2018
Figure Tamoxifen Picture
Figure Toremifene Picture
Figure Fulvestrant Picture
Table Global ER Targeted Drugs for Breast Cancer Revenue (Million USD) by Application (2014-2024)
Figure ER Targeted Drugs for Breast Cancer Revenue Market Share by Applications in 2018
Figure Hospital Picture
Figure Clinic Picture
Figure Drug Center Picture
Figure Other Picture
Table Global Market ER Targeted Drugs for Breast Cancer Revenue (Million USD) Comparison by Regions 2014-2024
Figure North America ER Targeted Drugs for Breast Cancer Revenue (Million USD) and Growth Rate (2014-2024)
Figure Europe ER Targeted Drugs for Breast Cancer Revenue (Million USD) and Growth Rate (2014-2024)
Figure Asia-Pacific ER Targeted Drugs for Breast Cancer Revenue (Million USD) and Growth Rate (2014-2024)
Figure South America ER Targeted Drugs for Breast Cancer Revenue (Million USD) and Growth Rate (2014-2024)
Figure Middle East and Africa ER Targeted Drugs for Breast Cancer Revenue (Million USD) and Growth Rate (2014-2024)
Figure Global ER Targeted Drugs for Breast Cancer Revenue (Million USD) and Growth Rate (2014-2024)
Table AstraZeneca Basic Information, Manufacturing Base and Competitors
Table AstraZeneca ER Targeted Drugs for Breast Cancer Type and Applications
Table AstraZeneca ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Sanofi Basic Information, Manufacturing Base and Competitors
Table Sanofi ER Targeted Drugs for Breast Cancer Type and Applications
Table Sanofi ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Pfizer Basic Information, Manufacturing Base and Competitors
Table Pfizer ER Targeted Drugs for Breast Cancer Type and Applications
Table Pfizer ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Mylan Basic Information, Manufacturing Base and Competitors
Table Mylan ER Targeted Drugs for Breast Cancer Type and Applications
Table Mylan ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Wockhardt Basic Information, Manufacturing Base and Competitors
Table Wockhardt ER Targeted Drugs for Breast Cancer Type and Applications
Table Wockhardt ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Cipla Basic Information, Manufacturing Base and Competitors
Table Cipla ER Targeted Drugs for Breast Cancer Type and Applications
Table Cipla ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Actiza Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table Actiza Pharmaceutical ER Targeted Drugs for Breast Cancer Type and Applications
Table Actiza Pharmaceutical ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Teva Basic Information, Manufacturing Base and Competitors
Table Teva ER Targeted Drugs for Breast Cancer Type and Applications
Table Teva ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Shanghai Forward Technology Basic Information, Manufacturing Base and Competitors
Table Shanghai Forward Technology ER Targeted Drugs for Breast Cancer Type and Applications
Table Shanghai Forward Technology ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Bayer Basic Information, Manufacturing Base and Competitors
Table Bayer ER Targeted Drugs for Breast Cancer Type and Applications
Table Bayer ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Liaoning Kangtai Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table Liaoning Kangtai Pharmaceutical ER Targeted Drugs for Breast Cancer Type and Applications
Table Liaoning Kangtai Pharmaceutical ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Fu 'an Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table Fu 'an Pharmaceutical Group ER Targeted Drugs for Breast Cancer Type and Applications
Table Fu 'an Pharmaceutical Group ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Yangtze River Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table Yangtze River Pharmaceutical Group ER Targeted Drugs for Breast Cancer Type and Applications
Table Yangtze River Pharmaceutical Group ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Amneal Pharms Basic Information, Manufacturing Base and Competitors
Table Amneal Pharms ER Targeted Drugs for Breast Cancer Type and Applications
Table Amneal Pharms ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Novartis Basic Information, Manufacturing Base and Competitors
Table Novartis ER Targeted Drugs for Breast Cancer Type and Applications
Table Novartis ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Intas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Intas Pharmaceuticals ER Targeted Drugs for Breast Cancer Type and Applications
Table Intas Pharmaceuticals ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Chemo Basic Information, Manufacturing Base and Competitors
Table Chemo ER Targeted Drugs for Breast Cancer Type and Applications
Table Chemo ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Accure Labs Basic Information, Manufacturing Base and Competitors
Table Accure Labs ER Targeted Drugs for Breast Cancer Type and Applications
Table Accure Labs ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Natco Basic Information, Manufacturing Base and Competitors
Table Natco ER Targeted Drugs for Breast Cancer Type and Applications
Table Natco ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Orion Corporation Basic Information, Manufacturing Base and Competitors
Table Orion Corporation ER Targeted Drugs for Breast Cancer Type and Applications
Table Orion Corporation ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Kyowa Hakko Kirin Basic Information, Manufacturing Base and Competitors
Table Kyowa Hakko Kirin ER Targeted Drugs for Breast Cancer Type and Applications
Table Kyowa Hakko Kirin ER Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Global ER Targeted Drugs for Breast Cancer Revenue (Million USD) by Players (2014-2019)
Table Global ER Targeted Drugs for Breast Cancer Revenue Share by Players (2014-2019)
Figure Global ER Targeted Drugs for Breast Cancer Revenue Share by Players in 2017
Figure Global ER Targeted Drugs for Breast Cancer Revenue Share by Players in 2018
Figure Global Top 5 Players ER Targeted Drugs for Breast Cancer Revenue Market Share in 2018
Figure Global Top 10 Players ER Targeted Drugs for Breast Cancer Revenue Market Share in 2018
Figure Global ER Targeted Drugs for Breast Cancer Revenue (Million USD) and Growth Rate (%) (2014-2019)
Table Global ER Targeted Drugs for Breast Cancer Revenue (Million USD) by Regions (2014-2019)
Table Global ER Targeted Drugs for Breast Cancer Revenue Market Share by Regions (2014-2019)
Figure Global ER Targeted Drugs for Breast Cancer Revenue Market Share by Regions (2014-2019)
Figure Global ER Targeted Drugs for Breast Cancer Revenue Market Share by Regions in 2018
Figure North America ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Europe ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Asia-Pacific ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure South America ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Middle East and Africa ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Table North America ER Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
Table North America ER Targeted Drugs for Breast Cancer Revenue Market Share by Countries (2014-2019)
Figure North America ER Targeted Drugs for Breast Cancer Revenue Market Share by Countries (2014-2019)
Figure North America ER Targeted Drugs for Breast Cancer Revenue Market Share by Countries in 2018
Figure USA ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Canada ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Mexico ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Table Europe ER Targeted Drugs for Breast Cancer Revenue (Million USD) by Countries (2014-2019)
Figure Europe ER Targeted Drugs for Breast Cancer Revenue Market Share by Countries (2014-2019)
Figure Europe ER Targeted Drugs for Breast Cancer Revenue Market Share by Countries in 2018
Figure Germany ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure UK ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure France ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Russia ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Italy ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Table Asia-Pacific ER Targeted Drugs for Breast Cancer Revenue (Million USD) by Countries (2014-2019)
Figure Asia-Pacific ER Targeted Drugs for Breast Cancer Revenue Market Share by Countries (2014-2019)
Figure Asia-Pacific ER Targeted Drugs for Breast Cancer Revenue Market Share by Countries in 2018
Figure China ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Japan ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Korea ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure India ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Southeast Asia ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Table South America ER Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
Table South America ER Targeted Drugs for Breast Cancer Revenue Market Share by Countries (2014-2019)
Figure South America ER Targeted Drugs for Breast Cancer Revenue Market Share by Countries (2014-2019)
Figure South America ER Targeted Drugs for Breast Cancer Revenue Market Share by Countries in 2018
Figure Brazil ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Argentina ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Colombia ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Table Middle East and Africa ER Targeted Drugs for Breast Cancer Revenue (Million USD) by Countries (2014-2019)
Table Middle East and Africa ER Targeted Drugs for Breast Cancer Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa ER Targeted Drugs for Breast Cancer Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa ER Targeted Drugs for Breast Cancer Revenue Market Share by Countries in 2018
Figure Saudi Arabia ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure UAE ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Egypt ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Nigeria ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure South Africa ER Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
Table Global ER Targeted Drugs for Breast Cancer Revenue (Million USD) by Type (2014-2019)
Table Global ER Targeted Drugs for Breast Cancer Revenue Share by Type (2014-2019)
Figure Global ER Targeted Drugs for Breast Cancer Revenue Share by Type (2014-2019)
Figure Global ER Targeted Drugs for Breast Cancer Revenue Share by Type in 2018
Table Global ER Targeted Drugs for Breast Cancer Revenue Forecast by Type (2019-2024)
Figure Global ER Targeted Drugs for Breast Cancer Market Share Forecast by Type (2019-2024)
Figure Global Tamoxifen Revenue Growth Rate (2014-2019)
Figure Global Toremifene Revenue Growth Rate (2014-2019)
Figure Global Fulvestrant Revenue Growth Rate (2014-2019)
Table Global ER Targeted Drugs for Breast Cancer Revenue by Application (2014-2019)
Table Global ER Targeted Drugs for Breast Cancer Revenue Share by Application (2014-2019)
Figure Global ER Targeted Drugs for Breast Cancer Revenue Share by Application (2014-2019)
Figure Global ER Targeted Drugs for Breast Cancer Revenue Share by Application in 2018
Table Global ER Targeted Drugs for Breast Cancer Revenue Forecast by Application (2019-2024)
Figure Global ER Targeted Drugs for Breast Cancer Market Share Forecast by Application (2019-2024)
Figure Global Hospital Revenue Growth Rate (2014-2019)
Figure Global Clinic Revenue Growth Rate (2014-2019)
Figure Global Drug Center Revenue Growth Rate (2014-2019)
Figure Global Other Revenue Growth Rate (2014-2019)
Figure Global ER Targeted Drugs for Breast Cancer Revenue (Million USD) and Growth Rate Forecast (2019-2024)
Table Global ER Targeted Drugs for Breast Cancer Revenue (Million USD) Forecast by Regions (2019-2024)
Figure Global ER Targeted Drugs for Breast Cancer Revenue Market Share Forecast by Regions (2019-2024)
Figure North America ER Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
Figure Europe ER Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
Figure Asia-Pacific ER Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
Figure South America ER Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
Figure Middle East and Africa ER Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)

Global HER-2 Targeted Drugs for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C2708 2019年8月 115Pages
本調査レポートは、乳癌用HER-2標的薬の世界市場について調べ、まとめました。種類別セグメントは、トラスツズマブ、ペルツズマブ、ラパチニブ、ネラチニブ、トラスツズマブエムタンシン、ピロチニブ、その他等、用途別セグメントは、病院薬局、小売薬局、オンライン薬局等に区分しました。乳癌用HER-2標的薬の世...

乳癌VEGF標的薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

Global VEGF Targeted Drugs for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C6127 2019年8月 119Pages
本調査レポートは、乳癌VEGF標的薬の世界市場について調べ、まとめました。種類別セグメントは、ベバシズマブ、ソラフェニブ、ラムシルマブ、スニチニブ、アパチニブ等、用途別セグメントは、病院、整形外科クリニック、外来手術センター、診断センター等に区分しました。乳癌VEGF標的薬の世界市場概観、企業動向、...

乳癌用標的薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

Global Targeted Drugs for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C5676 2019年7月 135Pages
本調査レポートは、乳癌用標的薬の世界市場について調べ、まとめました。種類別セグメントは、等、用途別セグメントは、病院、画像診断センター、癌研究所、その他等に区分しました。乳癌用標的薬の世界市場概観、企業動向、企業別乳癌用標的薬シェア、市場規模推移、市場規模予測（2019年-2024年）、主要地域分析...

乳癌用内分泌療法薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

Global Endocrine Therapy Drugs for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C2080 2019年8月 135Pages
本調査レポートは、乳癌用内分泌療法薬の世界市場について調べ、まとめました。種類別セグメントは、タモキシフェン、アナストロゾール、エキセメスタン、レトロゾール、ゴセレリン、フルベストラント等、用途別セグメントは、工業、農業、航空宇宙、防衛、その他等に区分しました。乳癌用内分泌療法薬の世界市場概観、企業...

小分子標的癌療法の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

Global Small Molecule Targeted Cancer Therapy Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C5252 2019年7月 122Pages
本調査レポートは、小分子標的癌療法の世界市場について調べ、まとめました。種類別セグメントは、モノクローナル抗体、小分子、小分子薬物コンジュゲート等、用途別セグメントは、等に区分しました。小分子標的癌療法の世界市場概観、企業動向、企業別小分子標的癌療法シェア、市場規模推移、市場規模予測（2019年-2...

骨がん治療薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

Global Bone Cancer Drugs Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C0880 2019年7月 120Pages
本調査レポートは、骨がん治療薬の世界市場について調べ、まとめました。種類別セグメントは、化学療法、標的療法等、用途別セグメントは、等に区分しました。骨がん治療薬の世界市場概観、企業動向、企業別骨がん治療薬シェア、市場規模推移、市場規模予測（2019年-2024年）、主要地域分析（北米、ヨーロッパ、ア...

胃癌薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

Global Stomach Cancer Drugs Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C5533 2019年7月 119Pages
本調査レポートは、胃癌薬の世界市場について調べ、まとめました。種類別セグメントは、化学療法薬、標的療法薬、生物学的療法、その他等、用途別セグメントは、等に区分しました。胃癌薬の世界市場概観、企業動向、企業別胃癌薬シェア、市場規模推移、市場規模予測（2019年-2024年）、主要地域分析（北米、ヨーロ...

乳がんPARP阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

Global PARP Inhibitors for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C4300 2019年8月 104Pages
本調査レポートは、乳がんPARP阻害剤の世界市場について調べ、まとめました。種類別セグメントは、オラパリブ、タラゾパリブ等、用途別セグメントは、携帯電話アクセサリー店、3C小売店、個人等に区分しました。乳がんPARP阻害剤の世界市場概観、企業動向、企業別乳がんPARP阻害剤シェア、市場規模推移、市場...

がん標的療法の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

Global Cancer Targeted Therapy Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C1008 2019年7月 135Pages
本調査レポートは、がん標的療法の世界市場について調べ、まとめました。種類別セグメントは、腫瘍抗原、臨床目的抗体開発、補体依存性細胞傷害（CDC）、シグナル伝達変化等、用途別セグメントは、等に区分しました。がん標的療法の世界市場概観、企業動向、企業別がん標的療法シェア、市場規模推移、市場規模予測（20...

乳がんCDK4 / 6阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）

Global CDK4/6 Inhibitors for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR08C1129 2019年7月 116Pages
本調査レポートは、乳がんCDK4 / 6阻害剤の世界市場について調べ、まとめました。種類別セグメントは、等、用途別セグメントは、子供、大人等に区分しました。乳がんCDK4 / 6阻害剤の世界市場概観、企業動向、企業別乳がんCDK4 / 6阻害剤シェア、市場規模推移、市場規模予測（2019年-2024...

乳癌用HER-2標的薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global HER-2 Targeted Drugs for Breast Cancer market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especia…
乳癌VEGF標的薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global VEGF Targeted Drugs for Breast Cancer market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especial…
乳癌用標的薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Targeted Drugs for Breast Cancer market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in…
乳癌用内分泌療法薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Endocrine Therapy Drugs for Breast Cancer market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, espe…
小分子標的癌療法の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Small Molecule Targeted Cancer Therapy market is valued at million USD in 2018 and is expected to reach million USD by the end of 2024, growing at a CAGR of between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in Chi…